New insights inside the interdigitating dendritic cell sarcoma-pooled analysis and review of literature

Ann Hematol. 2019 Dec;98(12):2641-2651. doi: 10.1007/s00277-019-03824-6. Epub 2019 Nov 18.

Abstract

Interdigitating dendritic cell sarcoma is a rare haematological neoplasm with high debatable management protocols. The data extracted from 127 case reports published between 1981 and 2018 were analysed. The median age at diagnosis was 58 years with a male to female ratio of 1.65:1. The median OS and PFS of IDCS were 12 and 6 months, respectively, with a disease-specific mortality rate of 36.4%. Two-thirds of patients had a localised disease, while 30% had a disseminated form with 1-year mortality rates of 21.1% and 78.9%, respectively. Twenty per cent of cases were associated with other malignancies. Histologically, the proliferation of large spindle-shaped cells with fascicular growth was described in 84.3% of cases. Based on Cox-regression model, surgical resection was the only treatment modality linked to survival improvement with no recorded survival benefits of radiotherapy and chemotherapy. The 1-year mortality rates in resected and non-resected disease were 17.8% and 63.2%, respectively (P < 0.0001).

Keywords: Associated cancer with IDCS; Dendritic cell neoplasm; Interdigitating dendritic cell sarcoma.

Publication types

  • Review

MeSH terms

  • Adult
  • Dendritic Cell Sarcoma, Interdigitating* / metabolism
  • Dendritic Cell Sarcoma, Interdigitating* / mortality
  • Dendritic Cell Sarcoma, Interdigitating* / pathology
  • Dendritic Cell Sarcoma, Interdigitating* / therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Models, Biological*
  • Survival Rate